Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study

for the Canadian Respiratory Research Network and teh CanCOLD Collaborative Research Group; for the CanCOLD Study Investigators

doi:10.1016/j.rmed.2018.11.006

Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study

for the Canadian Respiratory Research Network and teh CanCOLD Collaborative Research Group, for the CanCOLD Study Investigators

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

26 Citas (Scopus)

Resumen

Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health behaviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies have assessed associations between psychological distress and these behaviours among patients with vs without COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological disorders (depression, anxiety) and poor health behaviours (smoking, PA). Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD stage and COPD status. Results: Across the whole sample, we observed relationships between depression (β = 1.107 ± 0.197; 95%CI = 0.691–1.462; p <.001) and anxiety (β = 0.780 ± 0.170; 95%CI = 0.446–1.114; p <.001) and pack years. Higher depression (β = −0.220 ± 0.028; 95%CI = −0.275 to −0.165; p <.001) and anxiety (β = −0.091 ± 0.025; 95%CI = −0.139 to −0.043; p <.001) scores were related to lower PA. These associations were comparable across COPD and non-COPD patients. Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in this population.

Idioma original	English
Páginas (desde-hasta)	1-9
Número de páginas	9
Publicación	Respiratory Medicine
Volumen	146
DOI	https://doi.org/10.1016/j.rmed.2018.11.006
Estado	Published - ene. 2019

Nota bibliográfica

Funding Information:
There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR ( MFE: 146764 ) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research , the Canadian Respiratory Research Network , GlaxoSmithKline , Grifols , Aerocrine , and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work.

Funding Information:
There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR (MFE: 146764) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research, the Canadian Respiratory Research Network, GlaxoSmithKline, Grifols, Aerocrine, and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work.

Funding Information:
The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network ; industry partners are AstraZeneca Canada , Boehringer Ingelheim Canada Ltd. , GlaxoSmithKline Canada Ltd. , and Novartis . Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners were the CIHR ( CIHR/Rx&D Collaborative Research Program Operating Grants , 93326 ) and the Respiratory Health Network of the FRSQ ; industry partners were Almirall , Merck , Nycomed , Pfizer Canada Ltd. , and Theratechnologies .

Publisher Copyright:
© 2018

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine

Acceder al documento

10.1016/j.rmed.2018.11.006

Otros archivos y enlaces

Citar esto

Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. / for the Canadian Respiratory Research Network and teh CanCOLD Collaborative Research Group; for the CanCOLD Study Investigators.
En: Respiratory Medicine, Vol. 146, 01.2019, p. 1-9.

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

@article{e1433cf5737c4c469f605690cbed803f,

title = "Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study",

abstract = "Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health behaviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies have assessed associations between psychological distress and these behaviours among patients with vs without COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological disorders (depression, anxiety) and poor health behaviours (smoking, PA). Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD stage and COPD status. Results: Across the whole sample, we observed relationships between depression (β = 1.107 ± 0.197; 95%CI = 0.691–1.462; p <.001) and anxiety (β = 0.780 ± 0.170; 95%CI = 0.446–1.114; p <.001) and pack years. Higher depression (β = −0.220 ± 0.028; 95%CI = −0.275 to −0.165; p <.001) and anxiety (β = −0.091 ± 0.025; 95%CI = −0.139 to −0.043; p <.001) scores were related to lower PA. These associations were comparable across COPD and non-COPD patients. Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in this population.",

author = "{for the Canadian Respiratory Research Network and teh CanCOLD Collaborative Research Group} and {for the CanCOLD Study Investigators} and Paine, {Nicola J.} and Bacon, {Simon L.} and Jean Bourbeau and Tan, {Wan C.} and Lavoie, {Kim L.} and Aaron, {Shawn D.} and Chapman, {Kenneth R.} and FitzGerald, {J. Mark} and Paul Hernandez and Marciniuk, {Darcy D.} and Fran{\c c}ois Maltais and O'Donnell, {Denis E.} and Don Sin and Walker, {Brandie L.}",

note = "Funding Information: There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR ( MFE: 146764 ) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research , the Canadian Respiratory Research Network , GlaxoSmithKline , Grifols , Aerocrine , and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work. Funding Information: There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR (MFE: 146764) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research, the Canadian Respiratory Research Network, GlaxoSmithKline, Grifols, Aerocrine, and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work. Funding Information: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network ; industry partners are AstraZeneca Canada , Boehringer Ingelheim Canada Ltd. , GlaxoSmithKline Canada Ltd. , and Novartis . Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners were the CIHR ( CIHR/Rx&D Collaborative Research Program Operating Grants , 93326 ) and the Respiratory Health Network of the FRSQ ; industry partners were Almirall , Merck , Nycomed , Pfizer Canada Ltd. , and Theratechnologies . Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = jan,

doi = "10.1016/j.rmed.2018.11.006",

language = "English",

volume = "146",

pages = "1--9",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Psychological distress is related to poor health behaviours in COPD and non-COPD patients

T2 - Evidence from the CanCOLD study

AU - for the Canadian Respiratory Research Network and teh CanCOLD Collaborative Research Group

AU - for the CanCOLD Study Investigators

AU - Paine, Nicola J.

AU - Bacon, Simon L.

AU - Bourbeau, Jean

AU - Tan, Wan C.

AU - Lavoie, Kim L.

AU - Aaron, Shawn D.

AU - Chapman, Kenneth R.

AU - FitzGerald, J. Mark

AU - Hernandez, Paul

AU - Marciniuk, Darcy D.

AU - Maltais, François

AU - O'Donnell, Denis E.

AU - Sin, Don

AU - Walker, Brandie L.

N1 - Funding Information: There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR ( MFE: 146764 ) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research , the Canadian Respiratory Research Network , GlaxoSmithKline , Grifols , Aerocrine , and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work. Funding Information: There are no conflicts of interest relevant to the submitted work. NJP reports a postdoctoral fellowship from CIHR (MFE: 146764) outside of the submitted work. SLB reports personal fees from Sygesa Ltd, Schering-Plough, Merck, Boehringer-Ingelheim, Novartis, and grants from AbbVie outside of the submitted work. JB reports grants from Canadian Institutes of Health Research, the Canadian Respiratory Research Network, GlaxoSmithKline, Grifols, Aerocrine, and personal fees from Boehringer Ingelheim, AstraZeneca, and Novartis outside of the submitted work. WCT reports personal fees from Teva and GlaxoSmithKline, outside of the submitted work. KLL reports personal fees from Janssen, Bayer, Astra-Zeneca, Boehringer-Ingelheim, Astellas, AbbVie, and Novartis outside of the submitted work. Funding Information: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network ; industry partners are AstraZeneca Canada , Boehringer Ingelheim Canada Ltd. , GlaxoSmithKline Canada Ltd. , and Novartis . Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners were the CIHR ( CIHR/Rx&D Collaborative Research Program Operating Grants , 93326 ) and the Respiratory Health Network of the FRSQ ; industry partners were Almirall , Merck , Nycomed , Pfizer Canada Ltd. , and Theratechnologies . Publisher Copyright: © 2018

PY - 2019/1

Y1 - 2019/1

N2 - Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health behaviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies have assessed associations between psychological distress and these behaviours among patients with vs without COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological disorders (depression, anxiety) and poor health behaviours (smoking, PA). Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD stage and COPD status. Results: Across the whole sample, we observed relationships between depression (β = 1.107 ± 0.197; 95%CI = 0.691–1.462; p <.001) and anxiety (β = 0.780 ± 0.170; 95%CI = 0.446–1.114; p <.001) and pack years. Higher depression (β = −0.220 ± 0.028; 95%CI = −0.275 to −0.165; p <.001) and anxiety (β = −0.091 ± 0.025; 95%CI = −0.139 to −0.043; p <.001) scores were related to lower PA. These associations were comparable across COPD and non-COPD patients. Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in this population.

AB - Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health behaviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies have assessed associations between psychological distress and these behaviours among patients with vs without COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological disorders (depression, anxiety) and poor health behaviours (smoking, PA). Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD stage and COPD status. Results: Across the whole sample, we observed relationships between depression (β = 1.107 ± 0.197; 95%CI = 0.691–1.462; p <.001) and anxiety (β = 0.780 ± 0.170; 95%CI = 0.446–1.114; p <.001) and pack years. Higher depression (β = −0.220 ± 0.028; 95%CI = −0.275 to −0.165; p <.001) and anxiety (β = −0.091 ± 0.025; 95%CI = −0.139 to −0.043; p <.001) scores were related to lower PA. These associations were comparable across COPD and non-COPD patients. Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in this population.

UR - http://www.scopus.com/inward/record.url?scp=85056971098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056971098&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2018.11.006

DO - 10.1016/j.rmed.2018.11.006

M3 - Article

C2 - 30665505

AN - SCOPUS:85056971098

SN - 0954-6111

VL - 146

SP - 1

EP - 9

JO - Respiratory Medicine

JF - Respiratory Medicine

ER -

Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto